Please Support TMA During Myositis Awareness Month!   Click HERE! 

New Year’s Non-resolutions

Does the idea of New Year Resolutions stress you out? Here are some alternatives to this tradition that can add value to your year ahead without adding extra pressure.

Continue Reading

Vamorolone approved by FDA

Recently, the FDA announced the approval of a new drug, vamorolone, as a treatment for Duchenne muscular dystrophy (DMD), a genetic muscle disease that usually affects young boys. Understandably, this news hasn’t made a big splash in myositis circles, but it should. Vamorolone, marketed under the name Agamree, is a corticosteroid drug with a twist….

Continue Reading

IBM patients battle for veterans benefits

Recently, two members of TMA’s Military Veterans with Myositis Affinity Group were successful in acquiring disability benefits from the Veterans Administration. These benefits are significant. Not only are these former service members eligible to receive complete healthcare services and disability compensation, they can also access important benefits such as a travel allowance for medical appointments,…

Continue Reading

Paula Eichenbrenner joins TMA

Starting November 29, 2023, TMA will have a new executive director. After a months-long national search, TMA’s Board of Directors has found the perfect candidate to serve as TMA’s executive director. “We couldn’t be more delighted to welcome Paula Eichenbrenner to TMA,” says Board of Directors Chair Dave Mochel. “She possesses not just the business…

Continue Reading

Copay accumulator programs struck down

In a victory for patients, a federal judge recently struck down a policy that allowed health insurance plans to use copay accumulator and maximizer programs, thereby charging patients more for essential prescription medications. This is good news for those who live with myositis and want to use a manufacturer’s assistance coupon to help them afford…

Continue Reading